Get the Stockscreener App
3.04
3.05%
0.09
After Hours:
3.04
Cellectar Biosciences Inc stock is traded at $3.04, with a volume of 25,968.
It is up +3.05% in the last 24 hours and down -5.00% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
See More
Previous Close:
$2.95
Open:
$2.96
24h Volume:
25,968
Relative Volume:
0.41
Market Cap:
$12.89M
Revenue:
-
Net Income/Loss:
$-21.79M
P/E Ratio:
-0.4916
EPS:
-6.1838
Net Cash Flow:
$-23.12M
1W Performance:
+10.14%
1M Performance:
-5.00%
6M Performance:
-38.96%
1Y Performance:
+935.42%
1-Day Range:
$2.94
$3.06
1-Week Range:
$2.67
$3.06
52-Week Range:
$0.23
$10.19
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
3.04 | 12.51M | 0 | -21.79M | -23.12M | -6.1838 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Upgrade | Maxim Group | Hold → Buy |
| Dec-05-24 | Resumed | Ladenburg Thalmann | Buy |
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
View All
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences (CLRB) Begins Phase 1b Trial for Triple Ne - GuruFocus
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Triple Negative Breast Cancer - National Today
Cellectar Enrolls First Patient in CLR 125 Clinical Trial for Refractory Triple Negative Breast Cancer - National Today
Cellectar enrolls first patient in phase 1b cancer trial By Investing.com - Investing.com India
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) - The Manila Times
First patient joins Cellectar study for hard-to-treat breast cancer - Stock Titan
Cellectar Initiates Phase 1b Trial for Triple Negative Breast Cancer - Intellectia AI
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Aug Mood: Can Cellectar Biosciences Inc weather a recession2026 PostEarnings & Entry Point Strategy Guides - baoquankhu1.vn
CEO Moves: Is Cellectar Biosciences Inc a top pick in the sectorIPO Watch & Weekly Top Performers Watchlists - baoquankhu1.vn
Growth Value: Will Cellectar Biosciences Inc stock benefit from M AQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Trading Action: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Buybacks Report: How does Cellectar Biosciences Inc compare to its peersQuarterly Portfolio Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
VIX Spike: Can Cellectar Biosciences Inc weather a recessionTrade Risk Assessment & Community Verified Trade Alerts - baoquankhu1.vn
What drives Cellectar Biosciences Incs stock price2026 Risk Factors & Weekly High Potential Stock Alerts - baoquankhu1.vn
ETF Watch: Will WASH benefit from geopolitical trendsShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Big Money Moves: How cyclical is Cellectar Biosciences Incs revenue streamTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan
Meme Stocks: Can Cellectar Biosciences Inc disrupt its industryMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Patterns: How does Cellectar Biosciences Inc compare to its peers2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Layoff Watch: Will Cellectar Biosciences Inc stock benefit from M A2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Trading Recap: Can Cellectar Biosciences Inc weather a recessionWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
Risk Report: Does Cellectar Biosciences Inc have a sustainable dividendTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Rate Cut: Can Cellectar Biosciences Inc weather a recessionMarket Growth Report & Short-Term Trading Alerts - baoquankhu1.vn
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Buy at Maxim Group - Defense World
CLRB: Maxim Group Upgrades Cellectar Biosciences to Buy with $10 Target | CLRB Stock News - GuruFocus
Ideas Watch: Can Cellectar Biosciences Inc weather a recessionPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences Charts Risky Path to Approvals - TipRanks
Quarterly Trades: Does Cellectar Biosciences Inc have a sustainable dividendJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Can Cellectar Biosciences Inc weather a recessionWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Should you sell your Cellectar Biosciences stock? - Cantech Letter
Death Cross: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed to $21.8M in 2025, but new funding is needed beyond Q3 2026 - TradingView
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):